2-methyl-3-isopropylMi

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-methyl-3-isopropylMi
• 英文别名: 3-isopropyl-4-methyl-pyrrole-2,5-dione；3-Isopropyl-4-methyl-pyrrol-2,5-dion；3-Isopropyl-4-methyl-1H-pyrrole-2,5-dione；3-methyl-4-propan-2-ylpyrrole-2,5-dione
• 化学式: C₈H₁₁NO₂
• mdl: MFCD18810124
• 分子量: 153.181
• InChiKey: DTHMGFOCZDJOHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  红藻氨酸 在 乙醚 、 水 、 铬酸 、 溶剂黄146 作用下， 生成 2-methyl-3-isopropylMi
  参考文献：
  名称：

  Miyasaki, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 695,697

  摘要：

  DOI：

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS
  申请人：ORION CORPORATION

  公开号：US20160368906A1

  公开（公告）日：2016-12-22

  The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Cy 1 , Cy 2 , X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.

  本公开提供了公式（I）的双环杂环衍生物，可能在治疗上有用，更具体地作为溴结构域抑制剂；（I）中，R1、R2、R3、R4、L1、L2、Cy1、Cy2、X、n和虚线具有规范中给定的相同含义，以及其在治疗和预防疾病或疾病中有用，特别是在与溴结构域抑制剂相关的疾病或疾病中的使用。本公开还提供了制备化合物和包括至少一种公式（I）的双环杂环衍生物的药物配方，以及药学上可接受的载体、稀释剂或赋形剂。
• COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20150328208A1

  公开（公告）日：2015-11-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。
• The First Experimental Demonstration of Side Chain Extension of Geoporphyrins in Sediments
  作者：Kenta Asahina、Junya Asano、Gen Kumagai、Mitsuru Satou、Kouichi Nomoto、Yuichiro Kashiyama、Hajime Mita、Shinya Nomoto

  DOI：10.1246/cl.2010.1267

  日期：2010.12.5

  To investigate the formation process of high carbon number (>C32) sedimentary porphyrins, heating experiments of several porphyrins were performed. Chromic acid oxidation of the heating products of protoporphyrin IX dimethyl ester afforded 2-methyl-3-n-propylmaleimide as the predominant product among the side-chain extension products formed. On the other hand, saturated substituents of etioporphyrin were also extended on heating to slowly form normal and branched homologs. These results may suggest that the transalkylation of porphyrin side chains proceeds mainly by a regioselective mechanism involving alkyl radical addition to a vinyl group of chlorophylls or their diagenetic products.

  为了研究高碳数（>C32）沉积卟啉的形成过程，对几种卟啉进行了加热实验。将前卟啉IX二甲酸酯的加热产物进行铬酸氧化，得到了作为主要产物的2-甲基-3-n-丙基马来酰亚胺。此外，乙基卟啉的饱和取代基在加热过程中也被延伸，缓慢形成正常和支链同系物。这些结果可能表明，卟啉侧链的转烷基化主要通过一种区域选择性机制进行，该机制涉及烷基自由基与叶绿素或其成岩产物的乙烯基团的加成反应。
• Macroheterocyclic compounds as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20070088019A1

  公开（公告）日：2007-04-19

  This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disease, condition or disorder.

  本发明涉及宏环杂环化合物，可用作激酶或双重激酶抑制剂，制备这种化合物的方法以及用于治疗或改善激酶或双重激酶介导的疾病、状况或障碍的方法。
• Compositions and Methods for Treatment of Cancer
  申请人：Li Chiang J.

  公开号：US20100221251A1

  公开（公告）日：2010-09-02

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物及其制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯烷-2,5-二酮化合物的制药组合物。本发明提供了通过向需要治疗细胞增殖性疾病，例如癌症的患者施用本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯烷-2,5-二酮化合物的治疗有效量的方法。